Elanco Animal Health Again Cuts Annual Guidance After Mixed Q2 Earnings

  • Elanco Animal Health Inc ELAN has reported a Q2 adjusted EPS of $0.36, higher than the $0.28 reported a year ago, surpassing analysts' view of $0.25.
  • Revenue was $1.177 billion, a decrease of 8% Y/Y on a reported basis, or down 4%, excluding the unfavorable impact of foreign exchange rates, almost in line with the consensus of $1.18 billion.
  • Pet Health's revenue decreased by 11% (-7% CER) to $612 million, with a 1% increase in price partially offset by rebate and in-store marketing programs, primarily in the U.S. retail business.
  • Farm Animal revenue decreased 2% (+3% CER) as Rumensin sales were partially offset by pressured economics for swine and poultry producers in China and a decline for swine in Europe. 
  • Adjusted gross margin improved by 190 bps compared to 58.9%.
  • Guidance: Elanco expects FY22 revenue of $4.46 - $4.55 billion, down from previous guidance of $4.70 - $4.76 billion and the consensus of $4.69 billion.
  • It expects adjusted EPS of $1.06-$1.13, down from previous guidance of $1.15 - $1.21 (consensus of $1.14).
  • The company lowered adjusted EBITDA guidance to $1.06-$1.1 billion vs. the previous outlook of $1.12 - $1.16 billion.
  • For Q3, the company forecasts revenue of $1.01-$1.06 billion, below the consensus of $1.14 billion.
  • It expects adjusted EPS of $0.12 - $0.18 (consensus of $0.26) and adjusted EBITDA of $175 million - $215 million.
  • Price Action: ELAN shares are up 3.60% at $20.14 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLarge CapNewsGuidanceHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!